Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis
Portfolio Pulse from
Merit Medical Systems, Inc. has received FDA approval for its WRAPSODY Cell-Impermeable Endoprosthesis, allowing for its commercialization in the USA starting in 2025.
December 20, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merit Medical Systems has received FDA approval for its WRAPSODY Cell-Impermeable Endoprosthesis, paving the way for US commercialization in 2025.
FDA approval is a significant milestone for Merit Medical, allowing them to commercialize a new product in the US market. This is likely to positively impact their revenue and stock price in the short term as it opens up a new revenue stream.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100